Please provide your email address to receive an email when new articles are posted on . In patients with Graves’ orbitopathy, adding the immunosuppressant drug mycophenolate to glucocorticoid therapy ...

The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), CellCept for oral suspension, 200 mg/m; of Roche Palo Alto, LLC, it added. The approval bolsters the ...

Purpose: The pharmacology, pharmacokinetics, drug interactions, clinical efficacy, adverse effects, monitoring, and dosage and administration of enteric-coated (EC) mycophenolate sodium are reviewed.

Please provide your email address to receive an email when new articles are posted on . The FDA has granted a prior approval supplement to Zydus Lifesciences Limited allowing the company to market its ...

The Price section compares costs of the same generic drugs across brands and is purely for information purpose. Medindia neither buys nor sells drugs. Mycophenolate mofetil (Cellmune) is an ...

PHILADELPHIA, Aug. 30, 2021 /PRNewswire/ — Lannett Company, Inc. (NYSE: LCI) today announced that it has commenced marketing Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL, an internally ...

New research indicates that mycophenolate mofetil, a drug that is usually used to prevent rejection after kidney, heart or liver transplant, seems safe and effective in treating autoimmune hepatitis ...

Lannett is offering mycophenolate mofetil for oral suspension, 200 mg/mL, an internally developed product. The medication is the generic of Roche Palo Alto’s CellCept. It is indicated for the ...

The Prior Approval Supplement (PAS) granted by the US Food & Drug Administration (USFDA) is for Mycophenolate Mofetil for injection of strength 500 mg/vial, the generic equivalent of CellCept ...